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Edited by Beat ImhofAbstract The CC chemokine, monocyte chemoattractant pro-
tein-1 (MCP-1), plays a crucial role in the initiation of athero-
sclerosis and has direct eﬀects that promote angiogenesis. To
develop a speciﬁc inhibitor for MCP-1-induced angiogenesis,
we performed in vitro selection employing phage display random
peptide libraries. Most of the selected peptides were found to be
homologous to the second extracellular loops of CCR2 and
CCR3. We synthesized the peptide encoding the homologous se-
quences of the receptors and tested its eﬀect on the MCP-1 in-
duced angiogenesis. Surface plasmon resonance measurements
demonstrated speciﬁc binding of the peptide to MCP-1 but not
to the other homologous protein, MCP-3. Flow cytometry re-
vealed that the peptide inhibited the MCP-1 binding to THP-1
monocytes. Moreover, CAM and rat aortic ring assays showed
that the peptide inhibited MCP-1 induced angiogenesis. Our
observations indicate that the MCP-1-binding peptide exerts
its anti-angiogenic eﬀect by interfering with the interaction be-
tween MCP-1 and its receptor.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Peptide1. Introduction
Chemokines are inﬂammatory cytokines that play critical
roles in leukocyte recruitment during several pathological pro-
cesses [1]. Monocyte chemoattractant protein-1 (MCP-1) is a
chemokine implicated in a variety of inﬂammatory diseases,
such as atherosclerosis and rheumatoid arthritis [2,3]. The
recruitment of monocytes into the arterial subendothelium is
one of the earliest steps in the development of atherosclerosis,
and MCP-1 plays a crucial initiating role in this process [4,5].
MCP-1 is not expressed in normal endothelium, but it is in-
duced by diverse stimuli such as cytokines and oxidized ad-
ducts, and secreted by endothelial cells, smooth muscle and
macrophages.
Secreted MCP-1 binds to CCR2 (CC chemokine receptor 2)
with high aﬃnity and induces leukocyte chemotaxis [6,7]. The
extracellular amino terminal domain of CCR2 (amino acids 2–*Corresponding author. Fax: +82 2 793 0176.
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doi:10.1016/j.febslet.2005.01.07036) is critical for initiating binding, and one or more of its
extracellular loops may also be involved in binding [8,9].
MCP-1 selectively binds to its cognate receptor CCR2 [10]; it
also binds to the Eotaxin receptor CCR3 [11] with low aﬃn-
ity, but its biological signiﬁcance is not currently under-
stood [12]. Eotaxin is a natural antagonist of MCP-1,
presumably because it inhibits the MCP-1/CCR2 interaction
[13]. The basis of selective binding between chemokines and
their receptors is not clearly understood and is the subject of
current investigation [14].
Chemokines also regulate angiogenesis directly, as a conse-
quence of leukocyte inﬁltration, or growth factor expression
[15]. MCP-1 is the ﬁrst CC chemokine reported to play a direct
role in tumor angiogenesis, and eotaxin also induces in vivo
angiogenic responses by using endothelial cells expressing
CCR3 [16,17]. Even though the details of chemokine-induced
angiogenesis are not fully understood, therapy based on inhib-
iting the angiogenic function of MCP-1 could be of value for
inhibiting tumor progression and preventing the development
of atherosclerosis.
Phage libraries display random peptides as the coat protein
fusions on the surface of bacteriophage particles. They per-
mit rapid identiﬁcation of peptide ligands that contain motifs
for interacting with a target molecule, and may act as inhib-
itors of that target [18,19]. We used a phage display peptide
library to isolate peptides that bind to MCP-1. Interestingly,
most of the isolated peptides were homologous to the second
extracellular loops of CCR2 and CCR3, which were previ-
ously implicated to be involved in MCP-1 mediated signal
transduction. Most signiﬁcantly, CAM and rat aortic ring as-
says revealed that the second extracellular loop-mimetic pep-
tide inhibited MCP-1-induced angiogenesis. The selected
peptide could be useful as a lead molecule for anti-athero-
sclerosis therapy.2. Materials and methods
2.1. Biopanning of MCP-1-binding phages
Recombinant human MCP-1 was purchased from R&D Systems
(Minneapolis, MN, USA), and the phage-display peptide libraries
(Ph.D.-7 and Ph.D.-12) were from New England Biolabs. The phage
library was panned in 96-well plates coated with 0.15 ml MCP-1
(10 lg/ml) in 0.1 M NaHCO3 (pH 8.6) overnight at 4 C. The 96-well
microplates were then blocked with a blocking buﬀer (0.1 M NaHCO3
[pH 8.6], 0.5% BSA and 0.02% NaN3) for 2 h at 4 C, and 2 · 1011 pfu/
ml were added to the MCP-1-coated plates in the blocking buﬀer. After
incubation for 30 min at 25 C, unbound or weakly bound phages wereblished by Elsevier B.V. All rights reserved.
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by incubation for 8 min in 0.1 ml of elution buﬀer (0.2 M glycine–HCl
[pH 2.2] and 0.1% BSA). The recovered phages were used to infect
Escherichia coli ER2738 (NEB), ampliﬁed, puriﬁed by precipitation
with 1/6 vol PEG/NaCl (20% (w/w) polyethylene glycol 8000 and
2.5 M NaCl), and used for the next round of panning. After three
rounds, independent clones were isolated on LB/IPTG/X-gal plates,
and the phage titer was calculated from the number of plaques formed.
Twenty seven clones from the selection with the Ph.D.-7 library and
twenty clones from that with the Ph.D.-12 library were chosen and se-
quenced. Individual phage clones were puriﬁed by precipitation with
PEG/NaCl. Phage pellets were suspended in the iodide buﬀer (10
mM Tris–HCl [pH 8.0], 1 mM EDTA and 4 M Nal), single-strand
phage DNA was precipitated with ethanol, and the nucleotide se-
quences were determined. The primer used for sequencing was 5 0-
CCCTCATAGTTAGCGTAACG-3 0.2.2. Peptide synthesis
The selected peptide and mutant peptide were synthesized by Pep-
tron Inc. (Korea). Their sequences were HSWRHFHTLGGG and
HSARHAHTLGGG, respectively. The negative control peptide was
SHWDQPRPGLKP that binds to sialyl Lewis X carbohydrate [20].2.3. Biosensor assay
A BIAcore 3000 was used for the Surface Plasmon Resonance exper-
iments. After pre-activation, MCP-1 (R&D Systems) or MCP-3
(kindly provided by Dr. Key-Sun Kirn, Korea Institute of Science
and Technology) [21] was injected into one of the ﬂow cells and bind-
ing buﬀer into the other. After immobilizing the protein, the surface of
the chip was deactivated with 1 M ethanolamine hydrochloride, pH
8.5. When the baselines were stabilized, various concentrations of
the peptide were injected. Following each experiment, the sensor chip
was regenerated with 10 mM NaOH. Kinetic parameters were ob-
tained with the BIA evaluation program.2.4. Flow cytometric analysis
Monocytes of the human monocytic cell line THP-1 were cultured in
RPMI-1640 medium supplemented with 10% fetal bovine serum, 100
U/ml penicillin and 100 lg/ml streptomycin at 37 C. Binding of
MCP-1 to the surfaces of THP-1 cells was measured with Fluorokine
human MCP-1 biotin conjugate Cytokine Flow Cytometry Reagent
(R&D Systems). The cells were washed twice with PBS and suspended
in PBS containing 0.1% BSA at 1 · 105 cells/ml. Biotinylated rhMCP-1
or biotinylated unrelated protein (soybean trypsin inhibitor) were
mixed with peptide or anti-MCP-1 antibody and incubated for
30 min at 25 C. THP-1 cells were then added for 1 h at 4 C, and
the process was followed by addition of avidin–FITC as recommended
by the manufacturer (R&D Systems), and analyzed with a FACScan
ﬂow cytometer (Becton Dickinson).Fig. 1. Selection and sequencing of the phage-displayed peptides.
(A) Alignment of the selected peptides with the domains of CCR2 and
CCR3. The domains of the receptor are represented in schematic form,
and the number of peptide clones homologous to a given domain is
noted below the domain. The dotted box encloses the second
extracellular loop between transmembrane regions 4 (TM4) and 5
(TM5). (B) Sequence alignment between CCR2/CCR3 and the
peptides. The sequences of the second extracellular loop of CCR2
and CCR3 between TM4 and TM5 are shown together with the
sequences of the selected peptides. Peptide #1 was designed from
CCR3 (solid line) and M13 phage coat protein (dotted line). Peptide
#1 mutant has two point mutations (W to A and F to A).2.5. Chick chorioallantoic membrane (CAM) assay
Ovalbumin (4 ml) was removed from eggs with 3-day-old embryos.
Thereafter, windows were opened in each egg and covered with tape,
and the eggs were incubated at 37 C. On day 10, 15 ll of PBS, or
PBS containing MCP-1 and peptide, was applied to the center of cov-
erslips and allowed to dry for 1 h. Each coverslip was placed on the
chorioallantoic membrane of a chick and the eggs were incubated at
37 C for 3 days after which the assay was scored and photographed.
MCP-1 and PBS served as positive and negative controls, respectively.
The scores are presented as percentages of positive CAMs.
2.6. Rat aortic ring assay
Thoracic aortas were obtained from Sprague–Dawley rats. Excess
perivascular tissue was removed, transverse sections (1–2 mm) were
cut and the resulting aortic rings were washed in DMEM. The rings
were then embedded in matrigel (Becton Dickinson) in 96-well micro-
plates. After the matrigel had gelled, DMEM containing 2% serum to-
gether with PBS, MCP-1, and peptide were added to each well and the
plates were incubated at 37 C, with 5% CO2, for 3 days. After incuba-
tion the rings were photographed. The ring assays were performed
twice.3. Results
3.1. In vitro selection and synthesis of MCP-1 binding peptides
To select peptide ligands to MCP-1 we used two libraries
(Ph.D-7 and Ph.D-12) with peptides of 7 and 12 random ami-
no acids, respectively, displayed on the pIII coat protein of
phage Ml3. Recombinant human MCP-1 protein was the tar-
get for the phage selection. A signiﬁcant increase in relative
phage yield was obtained after three rounds of biopanning.
Of the 27 clones from the Ph.D.-7 library, 13 had identical se-
quences (designated 7-1) and the others were similar but not
identical. When we compared the peptide sequences to whole
sequences of CCR2 and CCR3, most of the selected peptide se-
quences were homologous to second extracellular loops be-
tween transmembranes 4 (TM4) and 5 (TM5) (Fig. 1A). In
particular, the peptide sequences were similar to the portion
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CCR3) which was also conserved between CCR2
(WNNFHTI) and CCR3 (WRHFHTL) (Fig. 1B). Since the
most frequently found peptide 7-1 was similar to the homolo-
gous sequences of CCR3 (WRH), we synthesized peptide #1
(HSWRHFHTLGGG) containing CCR3 amino acids 195–
201 (underlined) and ﬂanking sequences from Ml3 coat pro-
tein. As a control, we also synthesized peptide #1 mutant
(HSARHAHTLGGG) (Fig. 1B).
3.2. Binding of peptides to MCP-1
To quantify the binding aﬃnity of the peptide aptamer, we
used surface plasmon resonance (SPR) technology. An exam-Fig. 2. Binding of peptide #1 to MCP-1. (A) Surface Plasmon
Resonance (SPR) proﬁles of peptide #1, peptide #1 mutant, and NC
(negative control) to MCP-1 protein. Peptide concentrations were
100 lM. Dissociation constants (Kd) are presented as means of three
independent SPR measurements of the peptides to MCP-1 protein.
(B) SPR proﬁles of peptide #1 and peptide #1 mutant at the same
concentration (250 lM) to MCP-3 protein. (C) Peptide #1 inhibiting
MCP-1 binding to THP-1 cells. Binding of biotinylated MCP-1 on the
surface of THP-1 cells was determined by ﬂow cytometry in the
presence of peptides (#1 and #1 mut, 5 lM) or anti-MCP-1 antibody
(Ab, 5 lg/ml \, P < 0.01 versus MCP-1 alone). The histograms give the
percentages of binding relative to MCP-1 on its own, and are
means ± S.D. (error bars) of ﬁve independent experiments.ple of an SPR sensorgram to MCP-1 protein is shown in
Fig. 2A. When the same peptide concentrations were injected,
the binding proﬁle of peptide #1 (#1) was much more pro-
nounced than that of the #1 mutant (#1 mut.) or the negative
control (NC) peptide (SHWDQPRPGLKP) that binds to sia-
lyl Lewis X carbohydrates [20]. To conﬁrm the binding speci-
ﬁcity of the peptide #1 to MCP-1, the SPR proﬁles of peptide
#1 and #1 mutant were examined for the binding to the
homologous protein, MCP-3 (72% sequence identity to
MCP-1) (Fig. 2B). It was clearly demonstrated that the
MCP-1 binding peptide did not bind even to such a homolo-
gous chemokine. By injecting various concentrations of the
peptides under kinetic conditions, we obtained the dissociation
constants of peptide #1 to MCP-1 protein. The binding aﬃnity
of peptide #1 to MCP-1 was 2.20 ± 0.44 · 105 M, which was
extremely high aﬃnity for such a small size peptide evaluated
by SPR analysis. It was not appropriate to deﬁne the binding
aﬃnities for control peptides binding to MCP-1 as well as forFig. 3. Peptide #1 inhibiting MCP-1-induced angiogenesis in the chick
CAM assay. The photographs are of chorioallantoic membranes of
13-day-old embryos exposed to (A) PBS, (B) MCP-1 (10 ng/ml),
(C) MCP-1 plus peptide #1 (100 lM), (D)MCP-1 plus negative control
peptide (500 lM). Vessel numbers were scored and are presented as
percentages relative to MCP-1 treated CAM (E). Membranes exposed
to: MCP-1 (10 ng/ml), peptide #1 (#1, 100 lM and 500 lM), peptide
#1 mutant (#1 mut. 500 lM), negative control peptide (NC, 500 lM)
and anti-MCP-1 antibody (10 lg/ml). \, P < 0.001 versus MCP-1
alone. \\,P < 0.01 versus MCP-1 alone. Five to ten eggs were used for
each sample.
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most likely resulted from non-speciﬁc binding.
Since peptide #1 bound to MCP-1 with high aﬃnity in vitro,
we tested whether it could inhibit MCP-1 binding to THP-1
cells. FACS analysis showed that peptide #1 inhibited the
binding of biotin–MCP-1 to THP-1 cells up to 70% (Fig. 2C)
and the speciﬁcity of inhibition was conﬁrmed by comparison
with mutant #1 peptide and anti-MCP-1 antibody. Even
though the THP-1 cell is known to express high levels of
CCR2 on the cell surface, we do not know how the peptide
inhibits the MCP-1 from binding to THP-1 cells. Whatever
the mechanism, these results suggested that excess peptide #1
might compete with MCP-1 for binding to the surface of
THP-1 cells.3.3. Inhibition of angiogenesis by the peptide
Since peptide #1 bound to MCP-1, we tested whether it af-
fected MCP-1-induced angiogenesis. MCP-1 stimulates the
formation of robust new blood vessels, as shown by CAM as-
says (Fig. 3A and B). Application of excess amounts of peptide
#1 to the MCP-1 mixture greatly reduced the number of mi-
cro-vessels formed (Fig. 3C), and this anti-angiogenic eﬀect
was speciﬁc, since neither #1 mutant nor NC peptides (Fig.
3D) had a signiﬁcant inhibitory eﬀect. Quantiﬁcation of the
number of branch points revealed the speciﬁc inhibition by
peptide #1 (Fig. 3E). To investigate whether ex vivo angiogen-
esis was also stimulated by MCP-1, we used the rat aortic ring-
sprouting assay (Fig. 4). The control experiments in Fig. 4A
demonstrated that MCP-1-induced angiogenesis was not af-
fected by #1 mutant or NC peptides, whereas peptide #1
inhibited ring sprout formation in a dose-dependent manner
(Fig. 4B). We estimated that the inhibitory concentration
(IC50) of peptide #1 was around 10 lM.Fig. 4. Rat aortic ring assay. Capillary sprouting has occurred from the edge
capillary sprouting rings formed in response to PBS- (a, c, e, g) and MCP-
peptide #1 mutant (#1 mut. 100 lM, e and f) or negative control peptide (NC
to diﬀerent concentrations of peptide #1 together with PBS (a, c, e, g) or MC
100 lM (g and h). One representative ﬁgure from four experiments is shown4. Discussion
We have shown here that the small peptide derived from
the second extracellular loop of the receptor exerts an anti-
angiogenic eﬀect induced by MCP-1. Activation of the MCP-1
receptor (CCR2) is assumed to require two steps [8]. The ami-
no-terminal of CCR2 is the primary high aﬃnity binding site
for MCP-1 [9,22] and the other extracellular regions of the
receptor, such as the ﬁrst and second extracellular loops, are
secondary sites for low aﬃnity binding or for triggering a cel-
lular signal [8,23]. In fact, we found here that many of the se-
lected peptide sequences (26 from 47 phages) were partly
homologous to the conserved sequences of the second extracel-
lular loops of CCR2 and CCR3 (Fig. 1A). Some other peptides
were either similar to the amino-terminal of CCR2 or to the
ﬁrst extracellular loop of CCR3. Considering moderate se-
quence identity between CCR2 and CCR3 (49%), it seems sig-
niﬁcant to ﬁnd many peptides that are homologous to the
conserved sequences of the receptors. Based on the ﬁndings,
we designed the peptide #1 mimicking the second extracellular
loops as a speciﬁc decoy for the MCP-1 binding to the cells. As
expected, the peptide not only bound to MCP-1 but also inhib-
ited the angiogenic function of MCP-1 (Figs. 3 and 4). Since
the peptide was an eﬀective antagonist for MCP-1 induced
angiogenesis, it could provide clues to the basis of MCP-1 in-
duced angiogenesis involving the second extracellular loop of
the receptors. However, more study needs to be done to clearly
illuminate the inhibitory mechanism of the peptide for the
MCP-1 induced angiogenesis.
Phage displayed peptide selection is a powerful new tool for
molecular medicine. It has been used not only for targeting
speciﬁc cell types, such as tumor cells [24,25], but also for ﬁnd-
ing peptide antagonists for protein functions such as cell adhe-
sion and angiogenesis. In particular, anti-angiogenic peptidesof the ring in response to MCP-1 (10 ng/ml ). (A) Photographs showing
1- (b, d, f, h) to which anti-MCP-1 antibody (Ab, 10 lg/ml, c and d),
, 100 lM, g and h) were added. (B) Ring sprouting formed in response
P-1 (b, d, f, h): 0 lM (a and b), 10 lM (c and d), 50 lM (e and f) and
.
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angiogenesis is critically involved in tumor growth and metas-
tasis [26,27]. However, there have been no previous reports of
peptides directed against MCP-1-induced angiogenesis. In
view of the role of MCP-1 in atherosclerosis [28], inhibition
of MCP-1 induced angiogenesis could be extremely valuable
for anti-atherosclerosis therapy. Although RNA aptamers
have been obtained against MCP-1, their eﬀect on the angio-
genic function of MCP-1 was not tested [29]. Chemical antag-
onists of MCP-1 are also intensely searched [30]; however, an
antagonistic peptide should have the advantage of selectivity
over chemicals, and we suggest that peptide #1 could be a use-
ful starting point for developing an eﬀective anti-angiogenic
agent if its stability and aﬃnity can be enhanced.
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